Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedCyclic peptideFDA-approved 2023 · AphexdaStem cell mobiliser

Motixafortide

A CXCR4-blocking peptide that frees stem cells from the bone marrow before transplant

Motixafortide is a 14-amino-acid cyclic peptide that blocks CXCR4, the receptor holding blood-forming stem cells in the marrow. Approved as Aphexda in 2023, it is given with filgrastim so enough stem cells can be collected for transplant in multiple myeloma.

Manufacturer's recommended dosing (FDA label): 1.25 mg/kg (actual body weight), Once; a second dose may precede a third apheresis, Subcutaneous Details ↓

Overview

What is it?

People with multiple myeloma often receive high-dose chemotherapy and then a transplant of their own stem cells, which first have to be coaxed from the marrow into the blood and collected. Daily filgrastim is the standard, but many patients do not release enough cells with it alone. Stem cells are anchored by the CXCR4 receptor gripping the chemokine CXCL12; blocking that grip lets them go.

Motixafortide, developed as BKT140 and later BL-8040, binds CXCR4 more tightly than plerixafor, the older small-molecule drug that does the same job. In its first study, 18 patients with multiple myeloma given a single injection on top of a standard mobilisation regimen collected large numbers of CD34+ stem cells, which engrafted. In healthy volunteers, a single dose on its own mobilised enough cells for a one-day collection.

The decisive trial was GENESIS: with motixafortide, 92.5% of 122 patients collected the target number of cells within two apheresis sessions, against 26.2% with placebo. It was approved as Aphexda in September 2023. Its label warns of anaphylactic shock and hypersensitivity reactions, injection-site reactions, raised white cell counts and possible mobilisation of tumour cells, so it is not for patients with leukaemia. Trials in leukaemia and pancreatic cancer remain early.

Whether it beats the older drug is less clear. GENESIS compared motixafortide with placebo, not with plerixafor. The first real-world comparison, a 2026 single-centre study, found similar stem-cell yields and collection times, with 27 patients in each group reaching their target in one day, but more injection-site and systemic reactions with motixafortide that needed premedication and monitoring; that centre kept plerixafor as its default and reserved motixafortide for selected patients.

Who needs it at all is the practical question. The GENESIS protocol paper noted that about 45% of people with myeloma fail to mobilise optimally with filgrastim alone, and the trial set a target of 6 million CD34+ cells per kilogram, enough for more than one transplant. Collecting in fewer apheresis sessions means fewer hours attached to the machine and fewer days in clinic, which is where a mobilising drug earns its place.

Beyond stem-cell mobilisation, motixafortide has been tested as a cancer drug, on the idea that blocking CXCR4 pulls tumour cells out of protective niches and lets immune cells in. The results so far are mostly negative or early. In acute myeloid leukaemia, adding it to consolidation chemotherapy did not lengthen relapse-free survival in a randomised trial of 128 patients, though patients with high CXCR4 expression may have done better. In pancreatic cancer it produced no responses with atezolizumab after first-line treatment and modest results with pembrolizumab and chemotherapy, while a small first-line study with cemiplimab and chemotherapy reported responses in about half of 11 patients, a result now being tested in a randomised trial.

Its cancer rationale rests on a decade of animal work under its earlier codes. As BKT140 and BL-8040 it killed acute myeloid leukaemia cells, overcame the protection marrow stroma gives chronic myeloid leukaemia, cleared lymphoma from mouse marrow alongside rituximab, slowed lung cancer grafts, and even raised platelet counts after chemotherapy in mice. A structural study shows why it binds CXCR4 so tightly: six positive charges meet acidic pockets on the receptor while two bulky groups hold it in an inactive shape. For its approved use, a comparative review concludes that, absent a head-to-head trial, it looks pharmacologically better than plerixafor but not clearly more effective, and costs more.

92.5% vs 26.2%
target cells in ≤2 aphereses
GENESIS, 122 patients (2023) · PMID 37069359
88.8% vs 9.5%
target reached in one apheresis
GENESIS · PMID 37069359
1.25 mg/kg
label dose
once, 10–14 h before apheresis · Aphexda label
Not superior
vs plerixafor, real world
single centre, 2026
Science

Mechanism of Action

Motixafortide releases stem cells from the bone marrow by blocking the receptor that anchors them there.

⚓

CXCR4 blockade

Stem cells are held in the marrow by CXCR4 binding the chemokine CXCL12; motixafortide blocks CXCR4 and lets them move into the blood.

🔗

Tighter binding

It is a cyclic peptide that binds CXCR4 more tightly than plerixafor, the small-molecule drug with the same target, according to its developers' early work.

🩸

Working with filgrastim

Filgrastim expands stem cells over four days; motixafortide then releases them for collection the next morning.

⚠️

Tumour-cell mobilisation

Because it mobilises cells indiscriminately, the label warns it could mobilise leukaemic cells and it is not for patients with leukaemia.

Evidence

Published Research

The studies behind motixafortide, read from their PubMed abstracts, with dosing from the Aphexda label read October 3, 2026.

Human2023

GENESIS phase 3, 122 patients

With filgrastim, 92.5% on motixafortide collected at least 6 million CD34+ cells per kg within two apheresis sessions against 26.2% on placebo, and 88.8% against 9.5% in one session. The commonest side effects were transient grade 1 or 2 injection-site reactions: pain in 50%, redness in 27.5% and itching in 21.3%.

PMID: 37069359
Human2019

Why GENESIS was designed

The protocol paper notes that about 45% of patients with multiple myeloma fail to mobilise optimally with filgrastim alone, and sets the target of 6 million CD34+ cells per kg in up to two sessions.

PMID: 31495201
Human2014

First study in myeloma, 18 patients

Given once alongside cyclophosphamide and filgrastim at doses up to 0.9 mg/kg, it caused no grade 3 or 4 toxicity; at the top dose a single apheresis collected 20.6 million CD34+ cells per kg on average, and transplanted cells engrafted in a median of 12 days for neutrophils.

PMID: 24246358
Human2017

On its own in healthy volunteers

Single doses of 0.5 to 1 mg/kg raised blood CD34+ counts to about 31 to 37 cells per microlitre within four hours, against 8 on placebo; eight volunteers given 1 mg/kg collected an average of 11.6 million CD34+ cells per kg in one session.

PMID: 28835380
Human2020

Relapsed leukaemia, phase 2a

In 42 patients with relapsed or refractory acute myeloid leukaemia given motixafortide with high-dose cytarabine, the composite remission rate was 29% overall and 39% at the 1.5 mg/kg dose; it drove leukaemic cells out of the marrow into the blood.

PMID: 33270904
Human2020

Pancreatic cancer, COMBAT phase 2a

With pembrolizumab in 37 patients with chemotherapy-resistant metastatic pancreatic cancer, disease control was 34.5% and median survival 3.3 months; with added chemotherapy in 22 patients, the response rate was 32%. The authors called for randomised trials.

PMID: 32451495
Human2026

Real-world comparison with plerixafor

In a single centre, 29 of 30 motixafortide patients completed mobilisation; CD34+ yields and apheresis times were similar to plerixafor, with 27 per group collecting in one day, but motixafortide caused more injection-site and systemic reactions; the centre kept plerixafor as default.

PMID: 42435378
Human2026

Acute myeloid leukaemia consolidation, randomised

In a double-blind phase 2 trial, 128 patients with AML in first remission received high-dose cytarabine plus motixafortide or placebo. Median relapse-free survival did not differ (10.3 against 11.5 months). Exploratory analysis suggested patients with high CXCR4 expression relapsed less on motixafortide, a hypothesis for biomarker-selected trials.

PMID: 41980027
Human2021

Pancreatic cancer with pembrolizumab and chemotherapy (COMBAT)

In 43 patients with metastatic pancreatic cancer, motixafortide with pembrolizumab and nanoliposomal irinotecan-based chemotherapy gave a confirmed response rate of 13.2%, disease control in 63.2%, median progression-free survival of 3.8 months and overall survival of 6.6 months; grade 3 or higher neutropenia and infection occurred in 7%.

PMID: 34253578
Human2026

First-line pancreatic cancer with cemiplimab and chemotherapy

In the first stage of a single-arm phase 2 trial in 11 untreated patients, motixafortide, cemiplimab, gemcitabine and nab-paclitaxel produced confirmed partial responses in 55%, disease control in 91% and median progression-free survival of 9.7 months; a randomised phase 2 trial is under way.

PMID: 42811017
Human2026

Second-line pancreatic cancer with atezolizumab (MORPHEUS)

In an umbrella trial of previously treated metastatic pancreatic cancer, atezolizumab plus motixafortide produced no objective responses, with grade 3 to 5 adverse events in 53.3%; all the atezolizumab combinations tested had limited efficacy.

PMID: 41741368
Review2024

Against plerixafor, on paper

With no head-to-head trial, this comparative review finds motixafortide has the more favourable pharmacokinetics but similar efficacy to plerixafor in trials, and notes that cost, administration and monitoring may limit its use.

PMID: 38629183
In Vitro2023

How it binds CXCR4

Molecular simulations show its six positively charged residues pairing with acidic residues of CXCR4 while two bulky synthetic groups lock the receptor in inactive shapes, explaining its tight antagonist binding.

PMID: 36901829
Animal2017

Acute myeloid leukaemia

As BL-8040, it triggered apoptosis of AML cells by raising miR-15a/16-1 and lowering BCL-2, MCL-1 and cyclin D1; combined with BCL-2 or FLT3 inhibitors it prolonged survival of leukaemic mice and reduced residual disease.

PMID: 28280274
Animal2014

Chronic myeloid leukaemia with imatinib

As BKT140, it overcame the protection bone-marrow stroma gives CML cells, and with low-dose imatinib suppressed K562 tumour growth in mice by 95%.

PMID: 24502926
Animal2013

Lymphoma with rituximab

In a mouse model of disseminated non-Hodgkin lymphoma, BKT140 slowed tumour growth and reduced lymphoma cells in the marrow, by 93% when combined with rituximab.

PMID: 23637121
Animal2012

Lung cancer xenografts

BKT140 delayed the growth of H460 lung cancer xenografts, with a similar trend in A549, and added to the effects of chemotherapy and radiotherapy.

PMID: 22925564
Animal2013

Platelets after chemotherapy

In mice, repeated BKT140 stimulated megakaryocytes and platelet production and lessened the depth and length of thrombocytopenia after 5-fluorouracil.

PMID: 23906028
Dosing

Dosing Data

Motixafortide (Aphexda) is a single subcutaneous injection given after four days of filgrastim, 10 to 14 hours before the first apheresis.

Given in transplant centres with premedication; the label warns of anaphylactic shock and hypersensitivity reactions, so patients are observed afterwards.
ProtocolDoseFrequencyDurationRoute
Label: myeloma stem-cell mobilisation Approved labelAphexda prescribing information, section 2 (DailyMed set e704b2db, effective June 4, 2026)1.25 mg/kg (actual body weight)Once; a second dose may precede a third apheresis1 to 2 dosesSubcutaneous
First myeloma study (2014) Human studyPMID 24246358Up to 0.9 mg/kgOnceSingle doseSubcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Weight-based, given once
Aphexda is dosed at 1.25 mg/kg and prepared by the transplant pharmacy; there is no ongoing dose.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

Source: Aphexda (motixafortide injection) label, section 3 (DailyMed version 5, effective June 4, 2026).

Mixing a vial: a worked example

The approved product Aphexda (motixafortide injection) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “Reconstitute each vial with 2 mL of 0.45% Sodium Chloride Injection, USP at room temperature (20°C to 25°C (68°F to 77°F)) resulting in a concentration of 36.5 mg/mL of APHEXDA and permitting withdrawal of up to 1.7 mL (62 mg).”

Source: Aphexda (motixafortide injection) label, sections 2 and 3 (DailyMed version 5, effective June 4, 2026).

Storage before and after mixing

Before mixing or first use: “Store at 2°C to 8°C (36°F to 46°F) in original carton to protect from light.”

After mixing or first use: “Discard prepared reconstituted solution after 24 hours storage under refrigeration 2°C to 8°C (36°F to 46°F) or at room temperature 20°C to 25°C (68°F to 77°F) protected from light.” “If needed, store the reconstituted APHEXDA solution refrigerated at 2°C to 8°C (36°F to 46°F) or at room temperature at 20°C to 25°C (68°F to 77°F) for up to 24 hours protected from light.” “Discard unused portion of the drug.”

The label also sets storage out in a table that does not read well out of context: see section 16 of the label linked below.

Source: Aphexda (motixafortide injection) label, sections 16 and 2 (DailyMed version 5, effective June 4, 2026).

How it is taken

As the approved label gives it: Subcutaneous (Once; a second dose may precede a third apheresis; Label: myeloma stem-cell mobilisation).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of about 2 hours (effective, plasma). After about five half-lives almost none is left.

How long the doses were given: Label: myeloma stem-cell mobilisation: 1 to 2 doses.

When effects appear: unknown; no source on this page gives a time to effect for Motixafortide. Results reported in the studies are under Published Research.

Source: half-life: Aphexda prescribing information, section 12.3 (DailyMed set e704b2db, effective June 4, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Injection-site pain, redness and itching; Systemic and allergic-type reactions, reduced by premedication; Raised white cell counts; Injection-site reactions and systemic reactions needing intervention were more common than with plerixafor in a 2026 real-world comparison; Injection-site pain, redness and itching, and flushing, which premedication aims to reduce. Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Motixafortide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

Unknown: a PubMed search for human interaction studies of Motixafortide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Motixafortide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Motixafortide's expected mass, 2,159.5 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved. Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Injection-site pain, redness and itching
● Systemic and allergic-type reactions, reduced by premedication
● Raised white cell counts
● Injection-site reactions and systemic reactions needing intervention were more common than with plerixafor in a 2026 real-world comparison
● Injection-site pain, redness and itching, and flushing, which premedication aims to reduce

Contraindications & Cautions

Warnings from the Aphexda label (DailyMed, effective June 4, 2026).

● Anaphylactic shock and hypersensitivity reactions: premedication is required
● Injection-site reactions
● Tumour cell mobilisation in patients with leukaemia: not for use in leukaemia
● Leukocytosis
● Embryo-fetal toxicity
Questions

Frequently Asked Questions

?What is motixafortide used for?

With filgrastim, to move blood-forming stem cells from the marrow into the blood so they can be collected for an autologous transplant in multiple myeloma.

?How well does it work?

In the GENESIS trial, 92.5% of patients on motixafortide plus filgrastim reached the collection target within two apheresis sessions, against 26.2% on placebo plus filgrastim.

?Is it a peptide?

Yes: a synthetic 14-amino-acid cyclic peptide that blocks CXCR4.

?Is motixafortide better than plerixafor?

It has not been compared head to head in a randomised trial. A 2026 single-centre comparison found similar collections and more reactions with motixafortide.

?Why is premedication needed?

The label warns of anaphylactic shock and hypersensitivity reactions; patients receive premedication and are observed after the injection.

?Is it used in cancers other than myeloma?

Only in trials: early studies in acute myeloid leukaemia and pancreatic cancer reported modest results, and it is not approved for those uses.

?How many apheresis sessions are needed?

In GENESIS, 88.8% of patients on motixafortide reached the target in a single session, against 9.5% on placebo.

?What is apheresis?

A procedure in which blood is drawn through a machine that separates and collects stem cells and returns the rest; the cells are frozen for the later transplant. A session usually takes several hours, which is why reaching the target in fewer sessions matters to patients.

?Who makes motixafortide?

It was developed as BKT140 and later BL-8040; Drugs@FDA lists the Aphexda application, NDA 217159, approved in September 2023 for mobilising stem cells in multiple myeloma together with filgrastim.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): APHEXDA (motixafortide), NDA 217159, original approval September 8, 2023, prescription. Read October 3, 2026.
  2. [fda-pi] FDA. Aphexda (motixafortide) US prescribing information (DailyMed set e704b2db-f119-40ba-9346-9229e3281c9e, version 5, effective June 4, 2026). Read October 3, 2026.
  3. [pubmed] Crees ZD, et al. "Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial." Nat Med, 2023;29(4):869-879. PMID: 37069359.
  4. [pubmed] Crees ZD, et al. "GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma." Future Oncol, 2019;15(31):3555-3563. PMID: 31495201.
  5. [pubmed] Peled A, et al. "The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma." Clin Cancer Res, 2014;20(2):469-79. PMID: 24246358.
  6. [pubmed] Abraham M, et al. "Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34(+) Cells in Healthy Volunteers." Clin Cancer Res, 2017;23(22):6790-6801. PMID: 28835380.
  7. [pubmed] Borthakur G, et al. "BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study." Cancer, 2021;127(8):1246-1259. PMID: 33270904.
  8. [pubmed] Bockorny B, et al. "BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial." Nat Med, 2020;26(6):878-885. PMID: 32451495.
  9. [pubmed] Close S, et al. "Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience." Transfusion, 2026. PMID: 42435378.
  10. [clinical-trial] Ceran E, et al. "Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation." Blood, 2026;148(5):545-559. PMID: 41980027.
  11. [clinical-trial] Bockorny B, et al. "Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial." Clin Cancer Res, 2021;27(18):5020-5027. PMID: 34253578.
  12. [clinical-trial] Raufi AG, et al. "Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives." Nat Commun, 2026;17(1). PMID: 42811017.
  13. [clinical-trial] Manji GA, et al. "Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study." Oncologist, 2026;31(4). PMID: 41741368.
  14. [pubmed] Dietz L, et al. "A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection." J Oncol Pharm Pract, 2024;30(6):1073-1077. PMID: 38629183.
  15. [pubmed] Rebolledo-Bustillo M, et al. "Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor." Int J Mol Sci, 2023;24(5). PMID: 36901829.
  16. [pubmed] Abraham M, et al. "The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression." Leukemia, 2017;31(11):2336-2346. PMID: 28280274.
  17. [pubmed] Beider K, et al. "Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo." Mol Cancer Ther, 2014;13(5):1155-69. PMID: 24502926.
  18. [pubmed] Beider K, et al. "Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140." Clin Cancer Res, 2013;19(13):3495-507. PMID: 23637121.
  19. [pubmed] Fahham D, et al. "In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer." J Thorac Cardiovasc Surg, 2012;144(5):1167-1175.e1. PMID: 22925564.
  20. [pubmed] Abraham M, et al. "Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production." Br J Haematol, 2013;163(2):248-59. PMID: 23906028.

Sources & Citations

Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-05